MyBlueDots

Jointly active when it matters: Nerve cells in the eye work together to recognize contrast and movements

MyBlueDots6 months ago01 mins

The processing of optical information in the retina of the eye, where the light-sensitive photoreceptors and the first nerve cells are located, is one of the most energy-intensive processes in the organism, especially in view of the low relative weight of the retina.

MyBlueDots

Hippocratic AI Completes $141MM Series B Financing Round Led by Kleiner Perkins, Valuing the Company at $1.64B

MyBlueDots6 months ago01 mins

PALO ALTO, Calif.–(BUSINESS WIRE)– #GenAI–Strong customer traction, positive patient response, a recently granted patent, and achieving clinical safety drive company expansion

MyBlueDots

Hippocratic AI Launches AI Agent App Store for Healthcare

MyBlueDots6 months ago01 mins

PALO ALTO, Calif.–(BUSINESS WIRE)– #GenAI–Clinicians design, shape, and earn a share of revenue from AI agents that address the pressing challenges of patient care and operational efficiency.

Dietetics professor explains who should and should not embrace the latest weight-loss drugs

MyBlueDots6 months ago01 mins

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an increasingly popular option to consider: GLP-1s.

Enhanced rat genome map identifies over 1,100 new protein-coding genes

MyBlueDots6 months ago01 mins

A multi-institutional team of researchers has created a new and improved genetic map for the laboratory rat, a cornerstone in medical and scientific research. Known as GRCr8, this updated genome assembly enhances the ability to study human diseases, behaviors and genetic traits more precisely.

Study identifies TBK1 as key to overcoming CAR T resistance

MyBlueDots6 months ago01 mins

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, “TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids”.

Researchers find new biomarkers for osteoporosis diagnosis and treatment

MyBlueDots6 months ago01 mins

Researchers at Hospital for Special Surgery (HSS) have pinpointed a cellular target that could enhance the way osteoporosis and other metabolic bone diseases are diagnosed and treated. The findings, published recently in JCI Insight, reveal that circulating osteoclast precursor cells (cOCPs) play a pivotal role in bone loss. The study is also the first of its kind to establish a connection between cellular biomarkers and osteoporosis, offering a potential pathway for earlier detection and more effective therapies.

Transplant of frozen testicular tissue after chemotherapy during childhood provides hope for fertility restoration

MyBlueDots6 months ago01 mins

In boys who, before starting puberty, undergo radical treatments that can affect their fertility, testicular tissue can be preventively removed and frozen. This is done to preserve testicular stem cells, the precursors of sperm cells. Chemotherapy and radiation therapy can destroy these cells, leading to infertility later in life.

MyBlueDots

Oncology Based in-Vivo CRO Business Research Report 2024-2030: Expansion in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities – ResearchAndMarkets.com

MyBlueDots6 months ago01 mins

DUBLIN–(BUSINESS WIRE)–The “Oncology Based in-Vivo CRO – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Oncology Based In-Vivo CRO was estimated at US$1.5 Billion in 2023 and is projected to reach US$2.5 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Oncology-based In-

Science behind genetic testing for identifying risk of opioid misuse remains unproven, says study

MyBlueDots6 months ago01 mins

Opioid misuse and specifically opioid use disorder (OUD), continues to represent a significant U.S. public health threat, with more than 6 million Americans aged 12 and older meeting the criteria for OUD in 2022. Efforts to ease the crisis have included the development of genetic testing to identify individuals most at risk for OUD.

Useful _Links

Skin-like sensor can track body movement and electrical signals inside and out

AI and open-source software promise faster, easier biomedical imaging

Verbal response time reveals hidden sleepiness in older adults

Study shows sexual pleasure remains important for women across menopause transition

Lemurs show no age-related inflammation, challenging assumptions about human aging

Lemurs show no age-related inflammation, challenging assumptions about human aging

Jointly active when it matters: Nerve cells in the eye work together to recognize contrast and movements

Hippocratic AI Completes $141MM Series B Financing Round Led by Kleiner Perkins, Valuing the Company at $1.64B

Hippocratic AI Launches AI Agent App Store for Healthcare

Dietetics professor explains who should and should not embrace the latest weight-loss drugs

Enhanced rat genome map identifies over 1,100 new protein-coding genes

Study identifies TBK1 as key to overcoming CAR T resistance

Researchers find new biomarkers for osteoporosis diagnosis and treatment

Transplant of frozen testicular tissue after chemotherapy during childhood provides hope for fertility restoration

Oncology Based in-Vivo CRO Business Research Report 2024-2030: Expansion in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities – ResearchAndMarkets.com

Science behind genetic testing for identifying risk of opioid misuse remains unproven, says study

World News

Useful Links

Health

Business

Entertainment

About Us